Differential Expression of ATP6V1D and Its Diagnostic Potential in IgA Nephropathy

Abstract

Objective

IgA nephropathy (IgAN) is the most prevalent form of primary glomerular disease. However, its diagnosis is contingent on kidney biopsy. Therefore, noninvasive biomarkers are urgently needed for diagnosis. This study aims to identify novel urinary biomarkers that differentiate IgAN from other common primary glomerular diseases, specifically membranous nephropathy (MN) and minimal change disease (MCD).

Methods

The peripheral blood mononuclear cell (PBMC) transcriptome dataset GSE73953 was obtained from the GEO database. Differential gene expression, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment, Gene Ontology (GO) enrichment, and immune infiltration analyses were performed. Protein–protein interaction (PPI) analysis and lysosome-related genes were used to identify hub genes. The expression of the hub gene ATP6V1D in urine and kidney tissues from individuals with IgAN, healthy controls, MCD and MN patients was assessed using enzyme-linked immunosorbent assay (ELISA), Western blotting, and immunostaining techniques. Spearman’s correlation analysis was employed to investigate the relationships between the concentration of ATP6V1D in urine, the concentration of galactose-deficient IgA1 (GD-IgA1), and the clinical data of patients. The receiver operating characteristic (ROC) curve was used to assess the role of urine ATP6V1D levels in distinguishing IgAN from MN and MCD.

Results

ATPase was identified as the principal intracellular structure associated with differentially expressed genes (DEGs) between IgAN patients and healthy controls in PBMCs. ATP6V1D was identified as a hub gene at the intersection of lysosome-related and differential genes. ATP6V1D levels were lower in PBMCs, urine, and kidney samples from IgAN patients than in those from healthy individuals, MCD and MN patients. The decreased urinary ATP6V1D levels and increased GD-IgA1 levels in IgAN patients were further validated. These changes were positively correlated with 24-h urine protein levels. Notably, a negative correlation was observed between ATP6V1D and GD-IgA1 levels. ROC curve analysis demonstrated that urinary ATP6V1D (AUC = 0.972) and GD-IgA1 (AUC = 0.952) had significant discriminative power in distinguishing IgAN patients from MCD and MN patients, with no significant difference in predictive performance between the two biomarkers (P > 0.05).

Conclusions

The findings underscore the potential utility of the urine ATP6V1D concentration as a biomarker to distinguish IgAN from MN and MCD.

Keywords

IgA nephropathy / Peripheral blood mononuclear cells / Membranous nephropathy / Minimal change disease / Biomarker

References

[1] Eleni S, Claudia S, Sydney CWT, et al.. IgA nephropathy. Nat Rev Dis Primers, 2023, 9(1): 67-87

[2] Heather NR, Stéphan T, James WS, et al.. Remission of proteinuria improves prognosis in IgA nephropathy. JAm Soc Nephrol, 2007, 18(12): 3177-3183

[3] Daniel PG, Karen M, David W, et al.. Galactosylation of IgA1 Is Associated with Common Variation in C1GALT1. JAm Soc Nephrol, 2017, 28(7): 2158-2166

[4] Milada SH, Milan R, Henrik C, et al.. Aberrant O-glycosylation and anti-glycan antibodies in an autoimmune disease IgA nephropathy and breast adenocarcinoma. Cell Mol Life Sci, 2012, 70(5): 829-839

[5] Pamela S. Golgi glycosylation. Cold Spring Harb Perspect Biol, 2011, 3(4): a005199-a005199

[6] Yu-Shin S, Junji Y, Keisuke M, et al.. Golgi pH homeostasis stabilizes the lysosomal membrane through N-glycosylation of membrane proteins. Life Sci Alliance, 2024, 7(10): e202402677-e202402694

[7] Rebecca AO, Sergio CC, Stuti S, et al.. Breaking up and making up: The secret life of the vacuolar H(+) -ATPase. Protein Sci, 2017, 26(5): 896-909

[8] Nina O, Tomas H, Alzbeta V, et al.. Severe phenotype of ATP6AP1-CDG in two siblings with a novel mutation leading to a differential tissue-specific ATP6AP1 protein pattern, cellular oxidative stress and hepatic copper accumulation. JInherit Metab Dis, 2020, 43(4): 694-700

[9] Eric JRJ, Sharita T, Margret R, et al.. ATP6AP1 deficiency causes an immunodeficiency with hepatopathy, cognitive impairment and abnormal protein glycosylation. Nat Commun, 2016, 7: 11600-11612

[10] Vishwanathan H, Eva M, Uwe K, et al.. Loss-of-function mutations in ATP6V0A2 impair vesicular trafficking, tropoelastin secretion and cell survival. Hum Mol Genet, 2009, 18(12): 2149-2165

[11] Magda CS, Maria AR, Matias S. Mutations in ATP6AP2 cause autophagic liver disease in humans. Autophagy, 2018, 14(6): 1-2

[12] Van Damme T, Gardeitchik T, Mohamed M, et al.. Mutations in ATP6V1E1 or ATP6V1A Cause Autosomal-Recessive Cutis Laxa. American journal of human genetics, 2017, 100(2): 216-227

[13] Ying-Chun M, Li Z, Jiang-Hua C, et al.. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol, 2006, 17(10): 2937-2944

[14] Yasuyuki N, Daisuke O, Eri M, et al.. IFI27 Is a Useful Genetic Marker for Diagnosis of Immunoglobulin A Nephropathy and Membranous Nephropathy Using Peripheral Blood. PLoS One, 2016, 11(4): e0153252-e0153269

[15] Aaron MN, Chih Long L, Michael RG, et al.. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods, 2015, 12(5): 453-457

[16] Philippe B, Jérôme M, Frédéric E, et al.. jvenn: an interactive Venn diagram viewer. BMC Bioinformatics, 2014, 15(1): 293-299

[17] DeLong ER, DeLong DM, Clarke-Pearso DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics, 1988, 44(3): 837-845

[18] Bourdenx M, Daniel J, Genin E, et al.. Nanoparticles restore lysosomal acidification defects: Implications for Parkinson and other lysosomal-related diseases. Autophagy, 2016, 12(3): 472-483

[19] Ju-Hyun L, Mary Kate M, Devin MW, et al.. Presenilin 1 Maintains Lysosomal Ca(2+) Homeostasis via TRPML1 by Regulating vATPase-Mediated Lysosome Acidification. Cell Rep, 2015, 12(9): 1430-1444

[20] Wenhua L, Qianwen W, Junxia L, et al.. Machine learning-based prognostic modeling of lysosome-related genes for predicting prognosis and immune status of patients with hepatocellular carcinoma. Front Immunol, 2023, 14: 1169256-1169269

[21] Xiang F, Mei L, Zhengkun X, et al.. Use of liquid chromatography-tandem mass spectrometry to perform urinary proteomic analysis of children with IgA nephropathy and Henoch-Schönlein purpura nephritis. J Proteomics, 2020, 230: 103979-104002

[22] Qin Z, Wen-Ru W, Yi-Han L, et al.. Diagnostic and prognostic value of galactose-deficient IgA1 in patients with IgA nephropathy: an updated systematic review with meta-analysis. Front Immunol, 2023, 14: 1209394-1209406

[23] Koichi S, Kazuho H, Kazunari T, et al.. Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int, 2003, 63(6): 2286-2294

[24] Tadashi S, Masashi I, Taiga H, et al.. Latent IgA deposition from donor kidneys does not affect transplant prognosis, irrespective of mesangial expansion. Clin Transplant, 2013, 27: 14-21

[25] Kenji Y, Yusuke S, Hitoshi S, et al.. The kinetics of glomerular deposition of nephritogenic IgA. PLoS One, 2014, 9(11): e113005-e113012

[26] Li B, Liu T, Shen Y, et al.. TFEB/LAMP2 contributes to PM0.2-induced autophagy-lysosome dysfunction and alpha-synuclein dysregulation in astrocytes. Journal of environmental sciences (China), 2024, 145: 117-127

[27] Jonathan H, Gustavo CM, Andreas J. Ups and downs of lysosomal pH: conflicting roles of LAMP proteins?. Autophagy, 2023, 20(2): 437-440

[28] Qi C, Hanjing K, Doris Lou D, et al.. The different roles of V-ATPase a subunits in phagocytosis/endocytosis and autophagy. Autophagy, 2024, 20: 2297-2313

[29] Sarah KW, Helen Z, Shaher I, et al.. Human ApoE ɛ2 Promotes Regulatory Mechanisms of Bioenergetic and Synaptic Function in Female Brain: A Focus on V-type H+-ATPase. J Alzheimers Dis, 2016, 53(3): 1015-1031

[30] Baiping W, Heidi M-S, Chuangye Q, et al.. TFEB-vacuolar ATPase signaling regulates lysosomal function and microglial activation in tauopathy. Nat Neurosci, 2023, 27(1): 48-62

[31] Tomoki K, Takeshi I. CASM mediates LRRK2 recruitment and activation under lysosomal stress. Autophagy, 2024, 20(7): 1692-1693

[32] Yunna L, Yiming W, Liang K, et al.. Plasma exosomes impair microglial degradation of α-synuclein through V-ATPase subunit V1G1. CNS Neurosci Ther, 2024, 30(5): e14738-e14755

Funding

the Science and Technology Innovation Project of Hunan Province(2020SK51601)

the Health Commission of Hunan Province Scientific Research Projects(202203054127)

the Science and Technology Plan of Loudi City(202202)

RIGHTS & PERMISSIONS

The Author(s), under exclusive licence to Huazhong University of Science and Technology